Dimensional Fund Advisors LP Immuno Gen, Inc. Transaction History

Dimensional Fund Advisors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	SELL	$12.46 - $29.95 $9.05 Million - $21.8 Million	-726,531 Reduced 61.53%	454,213 $13.5 Million
Q3 2023 Nov 09, 2023	SELL	$14.09 - $19.87 $119,412 - $168,398	-8,475 Reduced 0.71%	1,180,744 $18.7 Million
Q2 2023 Aug 09, 2023	SELL	$3.75 - $20.05 $9,667 - $51,688	-2,578 Reduced 0.22%	1,189,219 $22.4 Million
Q1 2023 May 12, 2023	SELL	$3.67 - $4.92 $4.45 Million - $5.96 Million	-1,212,259 Reduced 50.43%	1,191,797 $4.58 Million
Q4 2022 Feb 09, 2023	SELL	$4.55 - $6.31 $622,417 - $863,176	-136,795 Reduced 5.38%	2,404,056 $11.9 Million
Q3 2022 Nov 10, 2022	BUY	$4.48 - $6.47 $4.17 Million - $6.02 Million	929,775 Added 57.71%	2,540,851 $12.1 Million
Q2 2022 Aug 12, 2022	BUY	$3.15 - $5.76 $5.07 Million - $9.28 Million	1,611,076 New	1,611,076 $7.25 Million
Q1 2022 May 13, 2022	SELL	$4.26 - $7.48 $87,402 - $153,467	-20,517 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$4.75 - $7.5 $487,867 - $770,317	-102,709 Reduced 83.35%	20,517 $152,000
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $2.04 Million - $2.68 Million	-406,595 Reduced 76.74%	123,226 $699,000
Q2 2021 Aug 12, 2021	BUY	$5.79 - $8.6 $3.07 Million - $4.56 Million	529,821 New	529,821 $3.49 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.